Profile data is unavailable for this security.
About the company
Boiron SA is a France-based pharmaceutical company engaged in the provision of homeopathic medicines. The Company develops, manufactures and markets single homeopathic medicines and drugs which are in the form of tablets, syrups, single-dose liquids and ointments. It also produces medicines based on trace elements, phytotherapy remedies, food supplements, as well as health and beauty care products. In addition, the Company owns a research center, which works for the development of homeopathy within the world of medicine. Boiron SA operates through a number of subsidiaries, which are based in Italy, Spain, Belgium, the Czech Republic, Slovakia, Russia, Romania, Poland, Hungary, the United States, Canada and Brazil, among others.
- Revenue in EUR (TTM)504.86m
- Net income in EUR19.37m
- Incorporated1967
- Employees2.74k
- LocationBoiron SA2 avenue de l ouest LyonnaisRONTALON 69510FranceFRA
- Phone+33 478456100
- Fax+33 478456291
- Websitehttps://www.boiron.fr/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Henan Taloph Pharmaceutical Stock Co Ltd | 218.27m | 5.73m | 468.07m | 2.21k | 75.58 | 2.41 | -- | 2.14 | 0.0884 | 0.0884 | 3.31 | 2.78 | 0.4791 | 2.74 | 1.60 | 807,429.60 | 1.45 | 0.3241 | 3.13 | 0.6105 | 23.45 | 26.22 | 3.02 | 0.6331 | 0.9038 | 1.86 | 0.3592 | 52.82 | -6.21 | 8.16 | 16.00 | 2.61 | -19.14 | -- |
| JCR Pharmaceuticals Co Ltd | 206.60m | -13.42m | 473.15m | 987.00 | -- | 1.75 | 184.91 | 2.29 | -19.98 | -19.98 | 307.86 | 379.76 | 0.3432 | 0.4534 | 2.50 | 38,039,510.00 | -2.21 | 5.86 | -3.77 | 9.33 | 70.45 | 73.83 | -6.45 | 13.60 | 0.668 | -- | 0.5295 | 45.13 | -22.86 | 5.94 | -186.42 | -- | 15.37 | 20.11 |
| Emergent Biosolutions Inc | 665.46m | 64.02m | 474.03m | 900.00 | 8.27 | 0.968 | 3.23 | 0.7123 | 1.29 | 1.29 | 14.20 | 11.05 | 0.5369 | 1.06 | 5.83 | 876,555.60 | 5.17 | -5.03 | 5.90 | -6.47 | 54.58 | 49.01 | 9.62 | -9.76 | 3.15 | 1.85 | 0.5324 | -- | -0.5432 | -1.15 | 74.94 | -- | -25.06 | -- |
| CorMedix Inc | 180.77m | 137.07m | 479.18m | 64.00 | 3.51 | 1.51 | 3.41 | 2.65 | 2.05 | 2.05 | 2.97 | 4.78 | 0.5174 | 0.8901 | 2.44 | 3,348,495.00 | 39.23 | -42.85 | 48.05 | -49.82 | 92.61 | 91.93 | 75.83 | -327.99 | 1.73 | -- | 0.2802 | -- | -- | 173.65 | 61.31 | -- | 25.91 | -- |
| Boiron SA | 504.86m | 19.37m | 479.87m | 2.74k | 24.52 | 1.29 | 7.82 | 0.9505 | 1.12 | 1.12 | 29.08 | 21.26 | 0.9021 | 1.30 | 6.51 | 182,193.40 | 3.46 | 4.01 | 4.34 | 5.04 | 73.71 | 73.23 | 3.84 | 5.81 | 1.46 | -- | 0.0467 | 66.42 | -1.15 | -2.63 | -68.36 | -22.53 | -15.75 | 2.71 |
| Shanghai Shen Lian Biomedical Corp | 35.75m | -3.70m | 484.34m | 391.00 | -- | 2.81 | -- | 13.55 | -0.0739 | -0.0739 | 0.713 | 3.43 | 0.1864 | 1.42 | 0.9144 | 748,865.90 | -2.21 | 3.53 | -2.40 | 3.80 | 57.36 | 73.49 | -11.87 | 16.93 | 3.64 | -- | 0.0106 | 43.52 | 0.6394 | 3.63 | -241.95 | -- | -3.99 | -- |
| Holder | Shares | % Held |
|---|---|---|
| Financi�re de l'�chiquier SAas of 31 Mar 2025 | 238.57k | 1.36% |
| Norges Bank Investment Managementas of 30 Jun 2025 | 182.45k | 1.04% |
| Gay-Lussac Gestion SAas of 31 Dec 2024 | 106.00k | 0.60% |
| HMG Finance SAas of 31 Dec 2025 | 100.05k | 0.57% |
| HC Capital Advisors GmbHas of 31 Oct 2025 | 89.26k | 0.51% |
| Dimensional Fund Advisors LPas of 05 Feb 2026 | 78.53k | 0.45% |
| DNCA Finance SAas of 31 Mar 2025 | 75.05k | 0.43% |
| Montaigne Capital SASas of 28 Nov 2025 | 42.87k | 0.24% |
| Amiral Gestion SAas of 31 Dec 2024 | 42.16k | 0.24% |
| Sycomore Asset Management SAas of 30 Jan 2026 | 30.12k | 0.17% |
